Investigation of neurodegenerative diseases from body fluid samples using Fourier transform infrared spectroscopy

Abstract

An intriguing feature of infrared (IR) spectroscopy is its capacity to accurately identify and characterize disease morphologies. It enables identification of molecular alterations in wide variety of physiological samples, including but not limited to isolated cellular specimens, body fluid samples and tissue biopsies without the need of using any external agents. Therefore, we aimed to summarize the recent findings on the uses of Fourier Transform IR (FTIR) spectroscopy in assessing the molecular alterations associated with neurodegenerative diseases, a specific group of diseases characterized by progressive and irreversible loss of neuronal cells. In this review, we focus on two specific disease situations, Multiple Sclerosis and Alzheimer’s disease, mainly due to the urgent need for identification of a reliable biomarker for their diagnosis. Body fluids, indeed, are very suitable specimens to be used in diagnosis, since they can be easily collected from patients and can accurately reflect biochemical changes. Precise identification of alterations in the molecular profile of body fluid samples from control and affected samples can enable us to identify biomarkers in the diagnosis of aforementioned diseases, and possibly as a crucial clue for developing therapeutical strategies. In this regard, we would like to present current advances in the use of FTIR spectroscopy along with various analysis tools, such as hierarchical cluster analysis (HCA), principal component analysis (PCA). Finally, we present the application of these techniques in Multiple Sclerosis and Alzheimer’s disease.

Keywords

Neurodegenerative diseases FTIR Multiple Sclerosis Alzheimer’s disease chemometry principle component analysis hierarchical cluster analysis cerebrospinal fluid serum diagnosis

Get full access to this article

View all access options for this article.

References

[1] Aarli

J.A.

Dua

Janca

and Muscetta

, Neurological Disorders: Public Health Challenges, World Health Organization Press, Geneva, 2006, pp. 41–110.

[2] Albert

M.S.

DeKosky

S.T.

and Dickson

, The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the national institute on aging and Alzheimer’s association workgroup, Alzheimer’s Dement. 7 (2011), 270–279.

[3] Anderson

N.L.

, The clinical plasma proteome: A survey of clinical assays for proteins in plasma and serum, Clin. Chem. 56(2) (2010), 177–185.

[4] Barnett

M.H.

Henderson

A.P.D.

and Prineas

J.W.

, The macrophage in MS: Just a scavenger after all? Pathology and pathogenesis of the acute MS lesion, Multiple Sclerosis 12 (2006), 121–132.

[5] Bayari

Sevinc

Tiftikcioglu

B.I.

Zorlu

and Severcan

, Molecular differentiation of mild cognitive impairment and dementia cases in Alzheimer’s disease using vibrational spectroscopy, in: 9th World Congress International Brain Research Organization, Rio de Janeiro, Brazil, 2015.

[6] Bermejo-Pareja

Antequera

Vargas

Molina

J.A.

and Carro

, Saliva levels of Abeta1-42 as potential biomarker of Alzheimer’s disease: A pilot study, BMC Neurol. 10 (2010), 108.

[7] Blennow

, Cerebrospinal fluid protein biomarkers for Alzheimer’s disease, NeuroRx 1 (2004), 213–225.

[8] Blennow

Hampel

Weiner

and Zetterberg

, Cerebrospinal fluid and plasma biomarkers in Alzheimer disease, Nat. Rev. Neurol. 6 (2010), 131–144.

[9] Boncheva

Damien

and Normand

, Molecular organization of the lipid matrix in intact Stratum corneum using ATR-FTIR spectroscopy, Biochim. Biophys. Acta 1778 (2008), 1344–1355.

10.

[10] Brück

, The pathology of multiple sclerosis is the result of focal inflammatory demyelination with axonal damage, J. Neurol. 252(Suppl. 5) (2005), V/3–V/9.

11.

[11] Burns

and Liffe

, Alzheimer’s disease, BMJ, Br. Med. J. Feb5 (2009), b158.

12.

[12] Burns

D.H.

Rosendahl

Bandilla

Maes

O.C.

Chertkow

H.M.

and Schipper

H.M.

, Near infrared spectroscopy of blood plasma for diagnosis of sporadic Alzheimer’s disease, J. Alzheimer’s Dis. 17 (2009), 391–397.

13.

[13] Cai

and Singh

B.R.

, A distinct utility of the amide III infrared band for secondary structure estimation of aqueous protein solutions using partial least squares methods, Biochem. J. 43 (2004), 2451–2459.

14.

[14] Caine

Heraud

Tobin

M.J.

McNaughton

and Bernard

C.C.A.

, The application of Fourier transform infrared microspectroscopy for the study of diseased central nervous system tissue, NeuroImage 59 (2012), 3624–3640.

15.

[15] Cakmak

Miller

L.M.

Zorlu

and Severcan

, Amifostine, a radioprotectant agent, protects rat brain tissue lipids against ionizing radiation induced damage: An FTIR microspectroscopic imaging study, Archives of Biochemistry and Biophysics 520 (2012), 67–73.

16.

[16] Carmona

Molina

Calero

Bermejo-Pareja

Martines-Martin

Alvarez

and Toledano

, Infrared spectroscopic analysis of mononuclear leukocytes in peripheral blood from Alzheimer’s disease patients, Anal. Bioanal. Chem. 402 (2012), 2015–2021.

17.

[17] Carmona

Molina

Calero

Bermejo-Pareja

Martines-Martinand

and Toledano

, Discrimination analysis of blood plasma associated with Alzheimer’s disease using vibrational spectroscopy, J. Alzheimer’s Dis. 34 (2013), 911–920.

18.

[18] Che Man

Y.B.

Syahariza

Z.A.

and Rohman

, Fourier transform infrared (FTIR) spectroscopy: Development, techniques, and application in the analyses of fats and oils, in: Fourier Transform Infrared Spectroscopy Oliver

, ed., Nova Science Publishers, New York, 2010, pp. 1–36, Chapter 1.

19.

[19] Chen

Tian

Baek

S.J.

Shang

X.I.

Park

Liu

Z.C.

Yao

X.Q.

Wang

J.Z.

Wang

X.H.

Cheng

Peng

Shen

A.G.

and Hu

J.M.

, Laser Raman detection of platelet as a non-invasive approach for early and differential diagnosis of Alzhemer’s disease, Laser Phys. Lett. 8 (2011), 547–552.

20.

[20] Chengxuan

Kivipelto

and von Strauss

, Epidemiology of Alzheimer’s disease: Occurrence, determinants, and strategies toward intervention, Dialogues Clin. Neurosci. 11 (2009), 111–128.

21.

[21] Choo

L.P.

Jackson

Halliday

W.C.

and Mantsch

H.H.

, Infrared spectroscopic characterisation of multiple sclerosis plaques in the human central nervous system, Biochim. Biophys. Acta 1182 (1993), 333–337.

22.

[22] Christensen

D.D.

, Alzheimer’s disease: Progress in the development of anti-amyloid disease-modifying therapies, CNS Spect. 12 (2007), 113–123.

23.

[23] Custers

Cauwenbergh

Bothy

J.L.

Courselle

De Beer

J.O.

Apers

and Deconinck

, ATR-FTIR spectroscopy and chemometrics: An interesting tool to discriminate and characterize counterfeit medicines, J. Pharm. Biomed. Anal. 112 (2015), 189–191.

24.

[24] De Leon

M.J.

DeSanti

Zinkowski

Mehta

P.D.

Pratico

Segal

Rusinek

Tsui

Saint Louis

L.A.

Clark

C.M.

Tarshish

Lair

Javier

Rich

Lesbre

Mosconi

Reisberg

Sadowski

DeBernadis

J.F.

Kerkman

D.J.

Hampel

Wahlund

L.O.

and Davies

, Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment, Neurobiol. Aging 27 (2006), 394–401.

25.

[25] Matas

S.L.A.

von Glehn

Fernandes

G.B.P.

and Soares

C.A.S.

, Cerebrospinal fluid analysis in the context of CNS demyelinating diseases, Arq. Neuro-Psiquiatr. 71(9B) (2013), 685–688.

26.

[26] Demir

Onde

and Severcan

, Phylogeny of cultivated and wild wheat species using ATR-FTIR spectroscopy, Spectrochim. Acta, Part A, Mol. Biomol. Spectrosc. 135 (2015), 757–763.

27.

[27] Dorling

K.M.

and Baker

M.J.

, Highlighting attenuated total reflection Fourier transform infrared spectroscopy for rapid serum analysis, Trends in Biotechnology 31(6) (2013), 327–328.

28.

[28] Du

Dodel

R.C.

Eastwood

B.J.

Bales

K.R.

Gao

Lohmuller

Muller

Kurz

Zimmer

Evans

R.M.

Hake

Gasser

Oertel

W.H.

Griffin

W.S.

Paul

S.M.

and Farlow

M.R.

, Association of an interleukin 1α polymorphism with Alzheimer’s disease, Neurology 55 (2000), 480–483.

29.

[29] Ergun

Demir

Uzbay

and Severcan

, Agomelatine strongly interacts with zwitterionic DPPC and charged DPPG membranes, Biochim. Biophys. Acta 1838 (2014), 2798–2806.

30.

[30] Fabian

Szendrei

G.I.

Mantsch

H.H.

and Otvos Jr.

, Comparative analysis of human and Dutch-type Alzheimer beta-amyloid peptides by infrared spectroscopy and circular dichroism, Biochem. Biophys. Res. Commun. 191 (1993), 232–239.

31.

[31] Fernandez-Montesinos

Torres

Baglietto-Vargas

Gutierrez

Gozes

Vitorica

and Pozo

, Activity-dependent neuroprotective protein (ADNP) expression in the amyloid precursor protein/presenilin 1 mouse model of Alzheimer’s disease, J. Mol. Neurosci. 41 (2010), 114–120.

32.

[32] Galozzi

Marcus

and Barkovits

, Amyloid-β as a biomarker for Alzheimer’s disease: Quantification methods in body fluids, Expert Rev. Proteomics 12 (2015), 343–354.

33.

[33] Ghiso

Calero

Matsubara

Governale

Chuba

Beavis

Wisniewski

and Frangione

, Alzheimer’s soluble amyloid β is a normal component of human urine, FEBS Lett. 408 (1997), 105–108.

34.

[34] Gok

Severcan

Goormaghtigh

Kandemir

and Severcan

, Differentiation of Anatolian honey samples from different botanical origins by ATR-FTIR spectroscopy using multivariate analysis, Food Chem. 170 (2015), 234–240.

35.

[35] Gold

Wolinsky

J.S.

Amato

M.P.

and Comi

, Evolving expectations around early management of multiple sclerosis, Ther. Adv. Neurol. Disord. 3(6) (2010), 351–367.

36.

[36] Goodin

D.S.

and Bates

, Treatment of early multiple sclerosis: The value of treatment initiation after a first clinical episode, Multiple Sclerosis 15(10) (2009), 1175–1182.

37.

[37] Griebe

Daffertshofer

Stroick

Syren

Nejad

P.A.

Neumaier

Backhaus

Hennerici

M.G.

and Fatar

, Infrared spectroscopy: A new diagnostic tool in Alzheimer disease, Neuroscience Letters 420 (2007), 29–33.

38.

[38] Gupta

V.B.

Laws

S.M.

Villemagne

V.L.

Ames

Bush

A.I.

Ellis

K.A.

Lui

J.K.

Masters

Rowe

C.C.

and Szoeke

, Plasma apolipoprotein E and Alzheimer’s disease risk, Neurology 76 (2011), 1091–1098.

39.

[39] Haines

J.D.

Inglese

and Casaccia

, Axonal damage in multiple sclerosis, Mount Sinai Journal of Medicine 78 (2011), 231–243.

40.

[40] Hands

J.R.

Dorling

K.M.

Abel

Ashton

K.M.

Brodbelt

Davis

Dawson

Jenkinson

M.D.

Lea

R.W.

Walker

and Baker

M.J.

, Attenuated Total Reflection Fourier Transform Infrared (ATR-FTIR) spectral discrimination of brain tumour severity from serum samples, J. Biophotonics 7 (2014), 189–199.

41.

[41] Hansson

Stomrud

Vanmechelen

Östling

Gustafson

D.R.

Zetterberg

Blennow

and Skoog

, Evaluation of plasma Ab as predictor of Alzheimer’s disease in older individuals without dementia: A population-based study, J. Alzheimer’s Dis. 28 (2012), 231–238.

42.

[42] Haris

and Severcan

, FTIR spectroscopic characterization of protein structure in aqueous and non-aqueous media, J. Molecular Catalysis: B (Enzymatic) 7 (1999), 207–221.

43.

[43] Heraud

Caine

Campanale

Karnezis

McNaughton

Wood

B.R.

Tobin

M.J.

and Bernard

C.C.A.

, Early detection of the chemical changes occurring during the induction and prevention of autoimmune-mediated demyelination detected by FT-IR imaging, NeuroImage 49 (2010), 1180–1189.

44.

[44] Hye

Lynham

Thambisetty

Causevic

Campbell

Byers

H.L.

Hooper

Rijsdijk

Tabrizi

S.J.

Banner

Shaw

C.E.

Foy

Poppe

Archer

Hamilton

Powell

Brown

R.G.

Sham

Ward

and Lovestone

, Proteome based plasma biomarkers for Alzheimer’s disease, Brain 129 (2006), 3042–3050.

45.

[45] Karşıdağ

Tüzün

Kemik

A.S.

Purisa

and Ünlü

, Alpha-1 protease inhibitor and antichymotyrpsin levels in acute pancreatitis, Ulus. Travma Acil Cer. 18 (2012), 195–199.

46.

[46] Kawarabayashi

and Shoji

, Plasma biomarkers of Alzheimer’s disease, Curr. Opin. Psychiatry 21 (2008), 260–267.

47.

[47] Keegan

B.M.

and Noseworthy

J.H.

, Multiple sclerosis, Annu. Rev. Med. 53 (2002), 285–302.

48.

[48] Kuo

Emmerling

M.R.

Lampert

H.C.

Hempelman

S.R.

Kokjohn

T.A.

Woods

A.S.

Cotter

R.J.

and Roher

A.E.

, High levels of circulating ab 42 are sequestered by plasma proteins in Alzheimer’s disease, Biochem. Biophys. Res. Commun. 257 (1999), 787–791.

49.

[49] Lambert

J.C.

Heath

Even

Campion

Sleegers

Hiltunen

Combarros

Zelenika

Bullido

M.J.

Tavernier

Letenneur

Bettens

Berr

Pasquier

Fiévet

Barberger-Gateau

Engelborghs

De Deyn

Mateo

Franck

Helisalmi

Porcellini

Hanon

, European Alzheimer’s Disease Initiative Investigators de Pancorbo

M.M.

Lendon

Dufouil

Jaillard

Leveillard

Alvarez

Bosco

Mancuso

Panza

Nacmias

Bossù

Piccardi

Annoni

Seripa

Galimberti

Hannequin

Licastro

Soininen

Ritchie

Blanché

Dartigues

J.F.

Tzourio

Gut

Van Broeckhoven

Alpérovitch

Lathrop

and Amouyel

, Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer’s disease, Nat. Genet. 41(10) (2009), 1094–1099.

50.

[50] Lassmann

, Recent neuropathological findings in MS-implications for diagnosis and therapy, J. Neurol. 251(Suppl. 4) (2004), IV/2–IV/5.

51.

[51] Levine

S.M.

and Wetzel

D.L.

, Chemical analysis of multiple sclerosis lesions by FT-IR microspectroscopy, Free Radical Biology & Medicine 25(1) (1998), 33–41.

52.

[52] Lewczuk

Kornhuber

Vanmechelen

Peters

Heuser

Maier

Jessen

Bürger

Hampel

Frölich

Henn

Falkai

Rüther

Jahn

Luckhaus

Perneczky

Schmidtke

Schröder

Kessler

Pantel

Gertz

H.J.

Vanderstichele

de Meyer

Shapiro

Wolf

Bibl

and Wiltfang

, Amyloid beta peptides in plasma in early diagnosis of Alzheimer’s disease: A multicenter study with multiplexing, Exp. Neurol. 223 (2010), 366–370.

53.

[53] Lewis

R.N.A.H.

and McElhaney

R.N.

, The structure and organization of phospholipid bilayers as revealed by infrared spectroscopy, Chem. Phys. Lipids 96 (1998), 9–24.

54.

[54] Liu

Zaidi

Igbal

Grundke-Igbal

Merkle

R.K.

and Gong

C.X.

, Role of glycosylation in hyperphosphorylation of tau in Alzheimer’s disease, FEBS Lett. 512 (2002), 101–106.

55.

[55] Liu

Qing

and Deng

, Biomarkers in Alzheimer’s disease analysis by mass spectroscopy-based proteomics, Int. J. Mol. Sci. 15(5) (2014), 7865–7882.

56.

[56] Lu

Zhu

X.-C.

Jiang

J.-T.

and Tan

, Body fluid biomarkers in Alzheimer’s disease, Ann. Transl. Med. 3 (2015), 70.

57.

[57] Lui

J.K.

Laws

S.M.

Q.X.

Villemagne

V.L.

Ames

Brown

Bush

A.I.

De Ruyck

Dromey

Ellis

K.A.

Faux

N.G.

Foster

Fowler

Gupta

Hudson

Laughton

Masters

C.L.

Pertile

Rembach

Rimajova

Rodrigues

Rowe

C.C.

Rumble

Szoeke

Taddei

Trounson

Ward

Martins

R.N.

and AIBL Research Group, Plasma amyloid-beta as a biomarker in Alzheimer’s disease: The AIBL study of aging, J. Alzheimer’s Dis. 20 (2010), 1233–1242.

58.

[58] Maccarrone

Bernardi

Finazzi Agrò

and Centonze

, Cannabinoid receptor signalling in neurodegenerative diseases: A potential role for membrane fluidity disturbance, Br. J. Pharmacol. 163(7) (2011), 1379–1390.

59.

[59] Maguregui

Knuutinen

Trebolazabala

Morillas

Castro

Martinez-Arkarazo

and Madariaga

J.M.

, Use of in situ and confocal Raman spectroscopy to study the nature and distribution of carotenoids in brown patinas from deteriorated wall painting in Marcus Lucretius House (Pompeii), Anal. Bioanal. Chem. 402 (2012), 1529–1539.

60.

[60] Mantsch

and Jackson

, Molecular spectroscopy in biodiagnostics (from Hippocrates to Herschel and beyond), J. Mol. Struct. 347 (1995), 187–206.

61.

[61] Mayeux

Honig

L.S.

Tang

M.X.

Manly

Stern

Schupf

and Metha

P.D.

, Plasma A[beta]40 and A[beta]42 and Alzheimer’s disease: Relation to age, mortality, and risk, Neurology 61 (2003), 1185–1190.

62.

[62] Miller

L.M.

, Characterization of neurodegenerative protein-misfolding diseases using FTIR spectroscopy and microspectroscopy, in: Vibrational Spectroscopy in Diagnosis and Screening Severcan

and Haris

P.I.

, eds, IOS Press, 2012, pp. 118–137.

63.

[63] Mitchell

A.L.

Gajjar

K.B.

Theophilou

Martin

F.L.

and Martin-Hirsch

P.L.

, Vibrational spectroscopy of biofluids for disease screening or diagnosis: Translation from the laboratory to a clinical setting, J. Biophotonics 7(3–4) (2014), 153–165.

64.

[64] Nakagawa

Kitazume

Oka

Maruyama

Saido

T.C.

Sato

Endo

and Hashimoto

, Sialylation enhances the secretion of neurotoxic amyloid-beta peptides, J. Neurochem. 96 (2006), 924–933.

65.

[65] Nakamura

Kelly

J.G.

Trevisan

Cooper

L.J.

Bentley

A.J.

Carmichael

P.L.

Scott

A.D.

Cotte

Susini

Martin-Hirsch

P.L.

Kinoshita

Fullwood

N.J.

and Martin

F.L.

, Microspectroscopy of spectral biomarkers associated with human corneal stem cells, Mol. Vision 16 (2010), 359–368.

66.

[66] Owens

G.L.

Gajjar

Trevisan

Fogarty

S.W.

Taylor

S.E.

Da Gama-Rose

Martin-Hirsch

P.L.

and Martin

F.L.

, Vibrational biospectroscopy coupled with multivariate analysis extracts potentially diagnostic features in blood plasma/serum of ovarian cancer patients, J. Biophotonics 7(3–4) (2014), 200–209.

67.

[67] Patel

Shah

R.J.

Coleman

and Sabbagh

, Potential peripheral biomarkers for the diagnosis of Alzheimer’s disease, Int. J. Alzheimer’s Dis. 2011 (2011), 572495.

68.

[68] Peuchant

Richard-Harston

Bourdel-Marchasson

Dartigues

J.F.

Letenneur

Barberger-Gateau

Arnaud-Dabernat

and Daniel

J.Y.

, Infrared spectroscopy: A reagent-free method to distinguish Alzheimer’s disease patients from normal-aging subjects, Transl. Res. 152 (2008), 103–112.

69.

[69] Polman

C.H.

Reingold

S.C.

Banwell

Clanet

Cohen

J.A.

Filippi

Fujihara

Havrdova

Hutchinson

Kappos

Lublin

F.D.

Montalban

O’Connor

Sandberg-Wollheim

Thompson

A.J.

Waubant

Weinshenker

and Wolinsky

J.S.

, Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria, Ann. Neurol. 69(2) (2011), 292–302.

70.

[70] Puntmann

V.O.

, How to guide on biomarkers: Biomarker definitions. Validation and applications with examples from cardiovascular disease, Postgrad. Med. J. 85 (2009), 538–545.

71.

[71] Querfurth

H.W.

and La Ferla

P.M.

, Alzheimer’s disease, N. Engl. J. Med. 362 (2010), 329–344.

72.

[72] Romeo

M.J.

Espina

Lowenthal

Espina

B.H.

Petricoin

E.F.

3rd. and Liotta

L.A.

, CSF proteome: A protein repository for potential biomarker identification, Expert Rev. Proteomics 2 (2005), 57–70.

73.

[73] Saez-Valero

Fodero

L.R.

Sjögren

Andreasen

Amici

Gallai

Vanderstichele

Vanmechelen

Parnetti

Blennow

and Small

D.H.

, Glycosylation of acetylcholinesterase and butyrylcholinesterase changes as a function of the duration of Alzheimer’s disease, J. Neurosci. Res. 72 (2003), 520–526.

74.

[74] Schipper

H.M.

, Biological markers for Alzheimer disease, Int. J. Alzheimer’s Dis. 2010 (2010), 387–392.

75.

[75] Schrader

, Infrared and Raman Spectroscopy: Methods and Applications, VCH, Weinheim, 1995.

76.

[76] Scott

D.A.

Renaud

D.E.

Krishnasamy

Meric

Buduneli

Cetinkalp

and Liu

K.Z.

, Diabetes-related molecular signatures in infrared spectra of human saliva, Diabetol. Metab. Syndr. 2 (2010), 48.

77.

[77] Severcan

Bozkurt

Gurbanov

and Gorgulu

, FT-IR spectroscopy in diagnosis of diabetes in rat animal model, J. Biophotonics 3(8–9) (2010), 621–631.

78.

[78] Severcan

and Haris

P.I.

, Introduction to vibrational spectroscopy in diagnosis and screening, in: Vibrational Spectroscopy in Diagnosis and Screening Severcan

and Haris

P.I.

, eds, IOS Press, 2012.

79.

[79] Severcan

Yonar

Ocek

and Zorlu

, The characterization and differential diagnosis of relapsing-remitting multiple sclerosis and clinically isolated syndrome from cerebro spinal fluids by infrared spectroscopy, in: 9th World Congress International Brain Research Organization, Rio de Janeiro, Brazil, 2015.

80.

[80] Shi

Sui

Peskind

E.R.

Hwang

Devic

Ginghina

Edgar

J.S.

Pan

Goodlett

D.R.

Furay

A.R.

Gonzalez-Cuyar

L.F.

and Zhang

, Salivary tau species are potential biomarkers of Alzheimer’s disease, J. Alzheimer’s Dis. 27 (2011), 299–305.

81.

[81] Sihlbom

Davidsson

and Nilson

C.L.

, Prefractionation of cerebrospinal fluid to enhance glycoprotein concentration prior to structural determination with FT-ICR mass spectroscopy, J. Proteome Res. 4 (2005), 2294–2301.

82.

[82] Sihlbom

Davidsson

Sjögren

Wahlund

L.O.

and Nilsson

C.L.

, Structural and quantitative comparison of cerebrospinal fluid glycoproteins in Alzheimer’s disease patients and healthy individuals, Neurochem. Res. 33 (2008), 1332–1340.

83.

[83] Smith

K.J.

and Lassmann

, The role of nitric oxide in multiple sclerosis, The Lancet Neurology 1 (2002), 232–241.

84.

[84] Snyder

H.M.

Carrillo

M.C.

Grodstein

Henriksen

Jeromin

Lovestone

Mielke

M.M.

O’Bryant

Sarasa

Sjøgren

Soares

Teeling

Trushina

Ward

West

Bain

L.J.

Shineman

D.W.

Weiner

and Fillit

H.M.

, Developing novel blood-based biomarkers for Alzheimer’s disease, Alzheimer’s Dement. 10 (2014), 109–114.

85.

[85] Sperling

R.A.

Aisen

P.S.

Beckett

L.A.

Bennett

D.A.

Craft

Fagan

A.M.

Iwatsubo

Jack

C.R.

Jr. Kaye

Montine

T.J.

Park

D.C.

Reiman

E.M.

Rowe

C.C.

Siemers

Stern

Yaffe

Carrillo

M.C.

Thies

Morrison-Bogorad

Wagster

M.V.

and Phelps

C.H.

, Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the national institute on aging and the Alzheimer’s association workgroup, Alzheimer’s Dement. 7 (2011), 280–292.

86.

[86] Sperling

R.A.

Jack

C.R.

Jr. and Aisen

P.S.

, Testing the right target and right drug at the right stage, Sci. Transl. Med. 3(111) (2011), 111cm33.

87.

[87] Stuart

B.H.

, Biological applications, in: Infrared Spectroscopy: Fundamentals and Applications, Wiley, New York, 2004, pp. 137–165.

88.

[88] Sunderland

Linker

Mirza

Putnam

K.T.

Friedman

D.L.

Kimmel

L.H.

Bergeson

Manetti

G.J.

Zimmermann

Tang

Bartko

J.J.

and Cohen

R.M.

, Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease, JAMA 289 (2003), 2094–2103.

89.

[89] Trapp

B.D.

Peterson

Ransohoff

R.M.

Rudick

Mork

and Bo

, Axonal transection in the lesions of multiple sclerosis, N. Engl. J. Med. 338 (1998), 278–285.

90.

[90] Turker

, Application of infrared spectroscopy in the study of neurological diseases, Biomedical Spectroscopy and Imaging 1(4) (2012), 303–323.

91.

[91] Turker

Severcan

Ilbay

and Severcan

, Epileptic seizures induce structural and functional alterations on brain tissue membranes, BBA Biomembranes 1838 (2014), 3088–3096.

92.

[92] Vogt

M.H.J.

Teunissen

C.E.

Iacobaeus

Heijnen

D.A.M.

Breij

E.C.W.

Olsson

Brundin

Killestein

and Dijkstra

C.D.

, Cerebrospinal fluid anti-myelin antibodies are related to magnetic resonance measures of disease activity in multiple sclerosis, J. Neurol. Neurosurg. Psychiatry 80 (2009), 1110–1115.

93.

[93] Wang

Xiao

Liu

Lin

Zhang

and Fang

, The efficacy of plasma biomarkers in early diagnosis of Alzheimer’s disease, Int. J. Geriatr. Psychiatry 29 (2014), 713–719.

94.

[94] Wormwood

K.L.

Aslebagh

Channaveerappa

Dupree

E.J.

Borland

M.M.

Ryan

J.P.

Darie

C.C.

and Woods

A.G.

, Salivary proteomics and biomarkers in neurology and psychiatryroteomics – clinical applications, Proteomics – Clin. Appl. 315 (2015), 1–30.

95.

[95] Wullschleger

Kapina

Molnarfi

Courvoisier

D.S.

Seebach

J.D.

Santiago-Raber

M.L.

Hochstrasser

D.F.

and Lalive

P.H.

, Cerebrospinal fluid interleukin-6 in central nervous system inflammatory diseases, PLoS ONE 8(8) (2013), e72399.

96.

[96] Yang

M.H.

Yang

Y.H.

C.Y.

Jong

S.B.

Chen

L.J.

Lin

Y.F.

S.J.

Chu

P.Y.

Chung

T.W.

and Tyan

Y.C.

, Activity-dependent neuroprotector homeobox protein: A candidate protein identified in serum as diagnostic biomarker for Alzheimer’s disease, J. Proteomics 75 (2012), 3617–3629.

97.

[97] Yonar

and Sunnetcioglu

M.M.

, Spectroscopic and calorimetric studies on trazodone hydrochloride-phosphatidylcholine liposome interactions in the presence and absence of cholesterol, BBA Biomembranes 1838 (2014), 2369–2379.